Ari M. Goldminz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ari M. Goldminz has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Andrew C. Wang
Department of Dermatology, Tufts Medical Center, Boston, MA, United States, United States
3 shared publicationsAlice B. Gottlieb
Department of Dermatology, Tufts Medical Center, Boston, Massachusetts
2 shared publicationsA.B. Gottlieb
1 shared publication- Alice B. Gottlieb
Department of Dermatology, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts
1 shared publication - Alice B. Gottlieb
Department of Dermatology, New York Medical College, Valhalla, New York
1 shared publication Alice Gottlieb
1 shared publication
Latest Publications
- 1 November 2016
- Published by Elsevier in Clinical Immunology
- Vol. 172, 61-64
Insights on methotrexate in psoriatic disease
- 1 November 2016
- Published by Elsevier in Clinical Immunology
- Vol. 172, 61-64
Insights on methotrexate in psoriatic disease
- 8 March 2016
- Published by Elsevier in Journal of Dermatological Science
- Vol. 82 (3) , 207-209
Methotrexate improves pro- and anti-atherogenic genomic expression in psoriatic skin
- 8 March 2016
- Published by Elsevier in Journal of Dermatological Science
- Vol. 82 (3) , 207-209
Methotrexate improves pro- and anti-atherogenic genomic expression in psoriatic skin
- Open Access
- 1 August 2015
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 151 (8) , 837-846
CCL20andIL22Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis
Psoriasis is a chronic immune-mediated disorder of dysregulated T-cell signaling that affects approximately 3% of the global population. Methotrexate sodium was first evaluated as a treatment for psoriasis in the 1950s, whereas newer biological agents, including adalimumab, were introduced in the 1990s. Studies have demonstrated the superior clinical efficacy and faster onset of the clinical response of adalimumab in the treatment of psoriasis compared with methotrexate.1,2 However, to our knowledge, no investigations have profiled the features of genomic, immunohistochemical, and messenger RNA (mRNA) expression that determine and differentiate responses of psoriatic disease to methotrexate and adalimumab. The primary objective of our study was to characterize the genomic, immunohistochemical, and mRNA signatures associated with methotrexate and adalimumab in the treatment of plaque-type psoriasis.
- 1 August 2015
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 151 (8) , 837-846
Open AccessCCL20andIL22Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis
Psoriasis is a chronic immune-mediated disorder of dysregulated T-cell signaling that affects approximately 3% of the global population. Methotrexate sodium was first evaluated as a treatment for psoriasis in the 1950s, whereas newer biological agents, including adalimumab, were introduced in the 1990s. Studies have demonstrated the superior clinical efficacy and faster onset of the clinical response of adalimumab in the treatment of psoriasis compared with methotrexate.1,2 However, to our knowledge, no investigations have profiled the features of genomic, immunohistochemical, and messenger RNA (mRNA) expression that determine and differentiate responses of psoriatic disease to methotrexate and adalimumab. The primary objective of our study was to characterize the genomic, immunohistochemical, and mRNA signatures associated with methotrexate and adalimumab in the treatment of plaque-type psoriasis.
- 9 September 2013
- Published by Wiley in Pediatric Dermatology
- Vol. 30 (6) , 700-705
Prevalence of the Metabolic Syndrome in Children with Psoriatic Disease
Adults with psoriasis have a greater risk of developing metabolic syndrome (MetS) and cardiovascular disease (CVD), but few studies have investigated the prevalence of MetS and other risk factors for CVD in children with psoriasis. In an assessor‐blinded study, 20 children ages 9–17 years with a current or previously documented history of psoriasis involving 5% or more of their body surface area or psoriatic arthritis were compared with a cohort of age‐ and sex‐matched controls with benign nevi, warts, or acne. MetS, our primary endpoint, was defined by the presence of abnormal values in at least three of the following measures: triglycerides, high‐density lipoprotein cholesterol (HDL‐C), fasting blood glucose (FBG), waist circumference, and blood pressure. Secondary endpoints included high‐sensitivity C‐reactive protein (hs‐CRP), total cholesterol (TC), and low‐density lipoprotein cholesterol (LDL‐C). Thirty percent (6/20) of children with psoriasis met the criteria for MetS, compared with 5% (1/20) of the control group (p < 0.05). Subjects with psoriasis had higher mean FBG (91.1 mg/dL) than the control group (82.9 mg/dL) (p = 0.01). There were no statistically significant differences in the other four components of MetS, BMI, BMI percentile, hs‐CRP, TC, or LDL‐C. The results of this trial demonstrate that children with psoriasis have higher rates of MetS than age‐ and sex‐matched controls. It may therefore be important to evaluate children with psoriasis for components of MetS to prevent future CVD morbidity and mortality.
- 9 September 2013
- Published by Wiley in Pediatric Dermatology
- Vol. 30 (6) , 700-705
Prevalence of the Metabolic Syndrome in Children with Psoriatic Disease
Adults with psoriasis have a greater risk of developing metabolic syndrome (MetS) and cardiovascular disease (CVD), but few studies have investigated the prevalence of MetS and other risk factors for CVD in children with psoriasis. In an assessor‐blinded study, 20 children ages 9–17 years with a current or previously documented history of psoriasis involving 5% or more of their body surface area or psoriatic arthritis were compared with a cohort of age‐ and sex‐matched controls with benign nevi, warts, or acne. MetS, our primary endpoint, was defined by the presence of abnormal values in at least three of the following measures: triglycerides, high‐density lipoprotein cholesterol (HDL‐C), fasting blood glucose (FBG), waist circumference, and blood pressure. Secondary endpoints included high‐sensitivity C‐reactive protein (hs‐CRP), total cholesterol (TC), and low‐density lipoprotein cholesterol (LDL‐C). Thirty percent (6/20) of children with psoriasis met the criteria for MetS, compared with 5% (1/20) of the control group (p < 0.05). Subjects with psoriasis had higher mean FBG (91.1 mg/dL) than the control group (82.9 mg/dL) (p = 0.01). There were no statistically significant differences in the other four components of MetS, BMI, BMI percentile, hs‐CRP, TC, or LDL‐C. The results of this trial demonstrate that children with psoriasis have higher rates of MetS than age‐ and sex‐matched controls. It may therefore be important to evaluate children with psoriasis for components of MetS to prevent future CVD morbidity and mortality.
- 1 September 2013
- Published by Frontline Medical Communications, Inc. in Seminars in Cutaneous Medicine and Surgery
- Vol. 32 (3) , 177-182
Noninfectious granulomatous dermatitides: a review of 8 disorders (Part 1 of 3).
In this review we focus on 2 of the noninfectious granulomatous dermatitides, granuloma annulare and interstitial granulomatous dermatitis (the remaining 6 will be discussed in Parts 2 and 3), with an overview of their clinical and histological presentations, differential diagnoses, and treatment options. The disorders we discuss are polymorphic in their clinical and histopathological presentations, follow chronic or undulating disease courses, and are typically recalcitrant to therapeutic interventions. Although the clinical history may be helpful, careful and thorough histopathological examination is required. Established treatment algorithms for these disorders are lacking, and no randomized, placebo-controlled studies have been published. Future investigations should focus on the evaluation of larger cohorts, not only to establish treatment recommendations in randomized, placebo-controlled trials, but also to reach a greater understanding of disease pathogenesis and clinical-pathological presentation.
- 1 September 2013
- Published by Frontline Medical Communications, Inc. in Seminars in Cutaneous Medicine and Surgery
- Vol. 32 (3) , 177-182
Noninfectious granulomatous dermatitides: a review of 8 disorders (Part 1 of 3).
In this review we focus on 2 of the noninfectious granulomatous dermatitides, granuloma annulare and interstitial granulomatous dermatitis (the remaining 6 will be discussed in Parts 2 and 3), with an overview of their clinical and histological presentations, differential diagnoses, and treatment options. The disorders we discuss are polymorphic in their clinical and histopathological presentations, follow chronic or undulating disease courses, and are typically recalcitrant to therapeutic interventions. Although the clinical history may be helpful, careful and thorough histopathological examination is required. Established treatment algorithms for these disorders are lacking, and no randomized, placebo-controlled studies have been published. Future investigations should focus on the evaluation of larger cohorts, not only to establish treatment recommendations in randomized, placebo-controlled trials, but also to reach a greater understanding of disease pathogenesis and clinical-pathological presentation.
- Top Cited Papers
- 1 February 2013
- Published by Elsevier in Journal of Dermatological Science
- Vol. 69 (2) , 89-94
NF-κB: An essential transcription factor in psoriasis
- 1 February 2013
- Published by Elsevier in Journal of Dermatological Science
- Vol. 69 (2) , 89-94
Top Cited PapersNF-κB: An essential transcription factor in psoriasis